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reatment lowers viral load to undetectable levels. Two controlled,
rospective studies in heterosexual couples have shown that treat-
ent virtually eliminates the risk of transmission.
Thus, if one could identify and treat all HIV-infected people
mmediately after infection, the HIV/AIDS epidemic would even-
ually disappear. In reality, not all people get tested, especially
hen they fear stigma and discrimination. In consequence not all
IV-infected individuals are known. This is particularly true for
he recently infected, who are also the most infectious. Not all of
hose HIV-positive individuals for whom the diagnosis is known
ave access to therapy, agree to be treated, or are taking therapy
ffectively. Someon effective treatmentwill stop, and in others, the
evelopment of resistance will lead to treatment failure.
In places like Vancouver and San Francisco, the majority of HIV-
ositive individuals are now under treatment, and the incidence of
ew HIV infections has recently fallen. However, correlation does
ot necessarily imply causation: In fact, the preventive potential
f anti-HIV drugs is unknown. Several large studies are starting in
012, using cluster randomization: a number of communities are
andomized to either receive the “test-and-treat” approach or con-
inue as before. Repeatedwaves of testingwould preciselymeasure
he incidence of HIV infection. Such trials face formidable logistical,
ractical and ethical obstacles.
Furthermore, resources are limited: should we provide drugs
o asymptomatic HIV-infected individuals without indication for
reatment according to guidelines in order to prevent HIV trans-
ission at the risk of diverting funding from sick patients in urgent
eed? Without deﬁnitive data, the intuitive appeal of “test-and-
reat” is unlikely to translate into action on a global scale. In the
eantime, based on the available evidence, we must strive to
rovide treatment to all those in medical need under the cur-
ent medical guidelines. This will contribute to a decrease in HIV
ransmissionwhile “test-and-treat” is fully explored in prospective
rials.
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reatment 2.0 and antiretroviral therapy for prevention
. Kato
WHO Vietnam, Hanoi, Viet Nam
At the end of 2010, 6.65million peoplewere receiving antiretro-
iral therapy (ART) globally, while more than 10 million people in
eed have not yet accessed the treatment. In 2011, United Nations
eneral Assembly set the global target to provide ART to 15 million
eople by 2015.
UNAIDS/WHO-proposed “Treatment 2.0” initiative aims to cat-
lyze the next phase of ART scale-up, through radical simpliﬁcation
f HIV treatment. Treatment 2.0 is designed to achieve and sustain
niversal access and maximize the preventive beneﬁts of ART by
mproving the efﬁciency and impact of HIV care and treatment pro-
rams in resource-limited countries. It ﬁve priority areas include:
) Optimize drug regimens, 2) Promote diagnostics using point of
are and other simpliﬁed technologies, 3) Reduce costs; 4) Adapt
elivery systems, and 5) Mobilize communities. Several countries
tarted to adopt Treatment 2.0 approaches.nfectious Diseases 16S (2012) e2–e157 e9
In Viet Nam, the Ministry of Health (MOH) initiated Treatment
2.0pilot in twoprovinces.HIV testingandcounseling (HTC)andART
delivery is being decentralized to primary health care stations. HTC
andART are also integrated into amethadonemaintenance therapy
(MMT) center. Peer educatorsworking for HIV prevention outreach
are trained for treatment literacy and supported to refer their peers
for repeated HIV testing. Rapid tests, once-day ﬁxed-dose combi-
nation ARV regimens and point-of-care CD4 technologies are being
introduced to simplify the procedures from HIV diagnosis to ART
initiation and life-long treatment.
Based the compelling evidence suggesting ART prevents HIV
transmission, WHO released the Guidelines on Couples HTC and
ART for treatment and prevention in HIV serodiscordant couples in
April 2012. Five Asian countries are now planning implementation
studies to operationalilze early ART for treatment and prevention,
while adapting the WHO Guidelines. ART has being proved to be a
powerful interventions to be included as part of the combination
HIV prevention framework.
To improve ART effectiveness at the population level, expanded
HTC to help people to know their HIV status, optimize drug reg-
imens, promote a functional continuum of prevention and care,
and effectively address themajor access and retention barriers (e.g.
stigma, discrimination, punitive laws) are essential.
http://dx.doi.org/10.1016/j.ijid.2012.05.027
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State of the Science – HIV Pre-Exposure Prophylaxis (PrEP)
S. Chariyalertsak
Research Institute for Health Sciences (RIHES), Chiang Mai, Thailand
HIV remains a signiﬁcant global health challenge with an esti-
mated 2.6 million people newly infected in 2009. The need of
effective HIV prevention interventions are very crucial for con-
trolling the epidemic especially among high-risk populations.
Pre-exposure prophylaxis (PrEP) refers to the use of antiretroviral
(ARV) medication either oral or topical by HIV-uninfected persons
prior to HIV exposure and continue during period of risk to prevent
HIV acquisition. The success of ARV drugs in preventing HIV trans-
mission from mothers to infants and in decreasing seroconversion
when given to adults shortly afterHIV exposure stimulated interest
in the concept of PrEP. An effective PrEP could provide an additional
safety net to sexually active persons at risk, when combined with
other HIV effective prevention strategies. Many clinical researches
are ongoing with ARV-based prevention or PrEP in different at risk
population across theworld including rectalmicrobicides andARV-
based vaginal ring. In the past few years, of seven PrEP trials with
available HIV endpoints, three different products have been tested
: tenoﬁvir 1% vaginal gel, oral tenofovirdisoproxilfumarate (TDF)
tablets, and TDF/emtricitabine (TDF/FTC or Truvada) tablets. All
found the products to be safe, and four (CAPRISA004 as topical
gel; and iPrEX, Partners PrEP, and TDF2 as oral PrEP) demonstrated
moderate effectiveness for HIV prevention when combined with
other HIV prevention strategies. On the other hand, the assess-
ment of oral Truvada in the FEM-PrEP study and of oral and vaginal
tenofovir in the VOICE study were stopped for futility by DSMB
in 2011. These discrepant results of PrEP studies are perplexing
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tal tool in the timely detection and management of public health
threats in India.
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nd need further investigated to understandmore about these con-
ict results. It might be possible that drug adherence or whether
harmacologic or local mucosal factors or others explained these
ariable efﬁcacy estimates. More challenging issues to come even
rEP can demonstrate the effectiveness to minimize the risk of HIV
nfection, but numerous questionswill remain about its implemen-
ation outside of the research context; such as intermittent use of
he drugs, inducing drug resistance, drug safety for long-term use,
osts of drug and appropriate monitoring program, risk compensa-
ion and combinationwith other effectiveHIVpreventionmethods.
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mplementingpre-exposure prophylaxis (PrEP) – Are we ready?
. Ananworanich
Deputy Director in Scientiﬁc Affairs, HIV-NAT and Chief, SEARCH,
angkok, Thailand
While global prevention strategies can guide PrEP implementa-
ion, determiningwhether and howPrEP should be implemented is
local decision that requires strong leadership andcountry-speciﬁc
pproaches best suited to combat local HIV epidemics. Optimal
rEP implementation ensures that it is integrated into existing ser-
ices as part of a multifaceted strategy that includes condom use,
exually-transmitted infections treatment, other proven preven-
ion approaches, behavior interventions to address adherence and
isk behavior, regular HIV testing, safety screening and long-term
onitoring. Clear policies are needed regarding for whom PrEP is
ecommended, whether cost of PrEP is subsidized and how PrEP is
istributed. Rights to access PrEP and delivery of PrEP in acceptable
nd non-stigmatizing settings are important considerations.
Sufﬁcient uptake of PrEP in populations at high risk for HIV is
rucial to impact HIV transmission, and active outreach to the hid-
en population is needed. Motivation for potential users to adopt
rEP could be driven by their own perceive risks, the efﬁcacy of
rEP and a perceived opportunity to safely engage in unprotected
ex. Communicationof PreP’s partial efﬁcacy is important andcould
lleviate misuse of PrEP as well as improve adherence to PrEP and
egularHIV testing. Cost, potential side effects and regularHIV test-
ng are some of the barriers to adopting PrEP. It is unlikely that
rEP implementationwill be successful in low- andmiddle-income
ountries unless it is heavily government-subsidized.
The process for constructing an optimal package for PrEP imple-
entation will vary between settings and will require input from
takeholders including policy makers, providers, potential users
nd advocacy groups. There is an urgent need for pilot PrEP imple-
entation programs to inform the optimal strategy prior to its
oll-out. Long-term monitoring of PrEP uptake, adherence, resis-
ance and cost-effectiveness will be important.
Thispresentationwill discuss recentﬁndingson issues related to
rEP implementation and will offer a perspective on implementing
rEP in Asian settings.
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Role of media scanning and veriﬁcation system as a supple-
mental tool to disease outbreak detection & reporting under
integrated disease surveillance project (IDSP)-India
R. Sharma1,∗, A. Karad2, B. Dash2, L. Chauhan2
1 Centers for Disease Control and Prevention, New Delhi, India
2 National Centre for Disease Control, New Delhi, India
Background:Media scanning can supplement conventional dis-
ease surveillance systems to more rapidly detect outbreaks so that
timely and appropriate action can be taken. To address this need in
India a Media Scanning & Veriﬁcation Cell (MSVC) was established
on July 2008 under the Integrated Disease Surveillance Project
(IDSP) at the National Centre for Disease Control (NCDC), Delhi.
Methods: Print, electronic media and television reports are
scanned manually for unusual health events daily by a team of
assistants. Unusual health events are analyzed by trained epi-
demiologists who generate Media Alerts that are disseminated
electronically to relevant State and District Health Ofﬁcers and fol-
lowed up by phone for veriﬁcation. VeriﬁedMedia Alert reports are
distributed to responsible health authorities and stakeholders for
appropriate public health action.
Results: A mean number of 4 Media Alert reports are gener-
ated each day. A total of 1685 alerts were reported in 42 months
(July 2008 to December 2011). Of these 1241 (73.7%) were veri-
ﬁed as real events and 183 (10.9%) were considered outbreaks by
local health ofﬁcials. Most events were from internet (57%) or print
media (24%) sources. Unusual health events were identiﬁed from
26 of 28 Indian States and 3 of 7 Union Territories with majority
reporting fromUttar Pradesh (21.1%), Delhi (8.6%), Karnataka (6.7%)
and Andhra Pradesh, Gujarat, West Bengal, Rajasthan, Haryana and
Orissa (5-6% each). The most common disease events identiﬁed
were food-borne and diarrhea (29.1%), dengue (10.68%), inﬂuenza
and respiratory disease (8.1%) and malaria (7.4%). The sensitivity of
MSVC to detect outbreaks was 14.8% with more than half of out-
breaks detected before they were identiﬁed by the conventional
surveillance system.
Conclusion: In India, the MSVC serves as an Early Warning
System gathering unconﬁrmed media reports of public health
signiﬁcance in real time and immediately disseminating the
information to the public health community electronically for
veriﬁcation and action. It often identiﬁes outbreaks before the con-
ventional reporting system, helping initiate an earlier response and
containment. It has proven to be a highly effective supplemen-
